Trial Profile

A Phase 1/2 trial to study the effect of SY-1365 for the treatment of patient with acute leukemia

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 23 May 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mevociclib (Primary)
Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Syros Pharmaceuticals

15 May 2017 Syros plans to initiate this trial based on the data from other trial (see profile 279117), as reported in a company media release.
26 Apr 2016 New trial record
20 Apr 2016 According to a Syros Pharmaceuticals media release, company plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in the second half of 2016 with the goal of initiating this study in acute leukemia in the first half of 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com